My­lan CEO Bresch hopes to tame the mob with a 50% dis­count for the EpiPen

Buck­ling un­der a storm of protest over its move to sys­tem­at­i­cal­ly raise the price of its life-sav­ing EpiPen by 500%, My­lan an­nounced this morn­ing that it will pro­duce a gener­ic of the au­to-in­jec­tor and sell it for $300, or half price to the brand­ed prod­uct.

CEO Heather Bresch, who has been the cen­ter of an in­tense pub­lic spot­light since the con­tro­ver­sy broke out, once again blamed the whole thing on the in­dus­try sup­ply chain. But that nev­er gar­nered much sym­pa­thy from an out­raged pub­lic, which saw the move as yet an­oth­er ex­am­ple of price goug­ing from an in­dus­try un­fet­tered by fed­er­al pric­ing re­stric­tions. One of the com­pa­ny’s few de­fend­ers was Mar­tin Shkre­li, the dis­graced biotech ex­ec oust­ed from two com­pa­nies and now await­ing tri­al on fraud charges. Hillary Clin­ton and a va­ri­ety of lead­ing politi­cians in Wash­ing­ton, DC, though, coun­tered by call­ing Bresch on the car­pet for prof­i­teer­ing, a hot top in drug in­dus­try cir­cles, which has been treat­ed to a steady se­ries of pric­ing scan­dals from Shkre­li, My­lan and Valeant.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.